Deprescription on oncological palliative care: an integrating review
Background: Patients on oncologic palliative care (OPC), due to diverse symptomatology and variable severity, tend to present polypharmacy that, although it seems justifiable in many cases, can pose health risks and negative consequences on patients’ quality of life. Thus, it is necessary to evalua...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN PT |
| Publicado: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/72ab9045ce7144e6b8f050f58805664f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background: Patients on oncologic palliative care (OPC), due to diverse symptomatology and variable severity, tend to present polypharmacy that, although it seems justifiable in many cases, can pose health risks and negative consequences on patients’ quality of life. Thus, it is necessary to evaluate the presence of possible therapeutic futilities, guiding the process of deprescription, in which there is a reduction in the amount of medication after reviewing the treatment objectives and assessing risks and benefits. Aim: The objective of this study was to identify the main classes of drugs that are candidates for the deprescribing for OPC patients by reviewing the literatura of the last 8 years. Methods: The bibliographic search was performed in the Medline and LILACS databases. Inclusion criteria were articles published between 2010 and 2018, which dealt with the topic of deprescription in CPO. The publications were analyzed for Qualis and the level of scientific evidence, in order to identify the main drugs candidates for deprescription. Results: Twenty articles were evaluated, being only 4 randomized clinical trials (RCTs), with level II of scientific evidence. Among the classes of drugs that are candidates for deprescription, the following stand out: statins (20.37%) and antihypertensives (20.07%). ECRs that corroborate with scientific evidence of quality need to be developed for guidelines that make it possible to prescribe, especially for the population in CPO. Conclusion: We highlight the importance of the use of tools to identify inappropriate medicines, and the use of medication conciliation as a means of identifying them, as well as pharmacotherapeutic follow-up.
|
|---|